EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts

Andrew B Adams, David Faber, Brendan P Lovasik, Abraham J Matar, Steven C Kim, Christopher Burlak iD, Matt Tector iD, Alfred J Tector iD

Xenotransplantation · 2024

DOI: 10.1111/xen.12880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Xenotransplantation, 2024. Verfasst von Andrew B Adams und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Macaca mulatta, Transplantation, Heterologous, Graft Survival, Kidney Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH NIAID, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the clinically relevant anti‐CD40 antibody iscalimab for baseline immunosuppression in a preclinical pig‐to‐rhesus renal xenograft model. Summary Background Data CD40/CD40L co‐stimulation blockade‐based immunosuppression has been more successful than calcineurin‐based protocols in prolonging xenograft survival in preclinical models.

Methods

GGTA1 knockout/CD55 transgenic pig kidneys were transplanted into rhesus monkeys ( n = 6) receiving an iscalimab‐based immunosuppressive regimen.

Results

Two grafts were lost early (22 and 26 days) because of ectatic donor ureters with otherwise normal histology. The other recipients survived 171, 315, 422, and 439 days with good renal function throughout the posttransplant course. None of the recipients experienced serious infectious morbidity.

Conclusions

It may be reasonable to evaluate an iscalimab‐based immunosuppressive regimen in clinical renal xenotransplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macaca mulattaTransplantation, HeterologousGraft SurvivalKidney TransplantationImmunosuppressive AgentsHeterograftsAnimalsSwineGraft RejectionAntibodies, Monoclonal, HumanizedAnimals, Genetically ModifiedAntibodies, MonoclonalHumansGalactosyltransferases

Stichwörter der Autor:innen

anti‐CD40 costimulation blockadeanti‐complement therapykidney transplantationxenotransplantation

Substanzen

Immunosuppressive AgentsAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalGalactosyltransferasesalpha-1,3-galactosyltransferase 1, porcine

Autor:innen und Institutionen

  • Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
  • Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
  • Makana Therapeutics, Miami, Florida, USA.

ORCID-Profile: Christopher Burlak, Matt Tector, Alfred J Tector

Förderung

  • NIH NIAID
  • Novartis

Zitieren

APA

Adams, A. B., Faber, D., Lovasik, B. P., Matar, A. J., Kim, S. C., Burlak, C., Tector, M., & Tector, A. J. (2024). Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts. Xenotransplantation. https://doi.org/10.1111/xen.12880

Vancouver

Adams AB, Faber D, Lovasik BP, Matar AJ, Kim SC, Burlak C, et al. Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts. Xenotransplantation. 2024. doi:10.1111/xen.12880

BibTeX
@article{Adams2024,
  author = {Adams, Andrew B and Faber, David and Lovasik, Brendan P and Matar, Abraham J and Kim, Steven C and Burlak, Christopher and Tector, Matt and Tector, Alfred J},
  title = {Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts},
  journal = {Xenotransplantation},
  year = {2024},
  doi = {10.1111/xen.12880}
}
Kostenlos starten →